These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 29790481)
1. Antiviral combination therapy for cytomegalovirus infection in high-risk infants. Vora SB; Brothers AW; Waghmare A; Englund JA Antivir Ther; 2018; 23(6):505-511. PubMed ID: 29790481 [TBL] [Abstract][Full Text] [Related]
2. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients]. Li L; Wang Y; Yan CH; Huang XJ Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863 [No Abstract] [Full Text] [Related]
3. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report. Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406 [TBL] [Abstract][Full Text] [Related]
4. Is combination antiviral therapy for CMV superior to monotherapy? Drew WL J Clin Virol; 2006 Apr; 35(4):485-8. PubMed ID: 16387546 [TBL] [Abstract][Full Text] [Related]
5. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study. Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651 [TBL] [Abstract][Full Text] [Related]
6. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection. Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775 [TBL] [Abstract][Full Text] [Related]
7. Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocompromised child. Iwasenko JM; Scott GM; Ziegler JB; Rawlinson WD J Clin Virol; 2007 Oct; 40(2):152-5. PubMed ID: 17698411 [TBL] [Abstract][Full Text] [Related]
8. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients]. Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666 [TBL] [Abstract][Full Text] [Related]
9. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients. Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A; Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510 [TBL] [Abstract][Full Text] [Related]
10. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients. Bacigalupo A; Boyd A; Slipper J; Curtis J; Clissold S Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1249-64. PubMed ID: 23167560 [TBL] [Abstract][Full Text] [Related]
12. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. Reddy AJ; Zaas AK; Hanson KE; Palmer SM J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480 [TBL] [Abstract][Full Text] [Related]
13. Ganciclovir and foscarnet dual-therapy for cytomegalovirus encephalitis: A case report and review of the literature. Baghban A; Malinis M J Neurol Sci; 2018 May; 388():28-36. PubMed ID: 29627026 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides. Sakamoto K; Nakasone H; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Ashizawa M; Sato M; Terasako-Saito K; Machishima T; Kimura S; Kikuchi M; Kako S; Kanda J; Yamazaki R; Tanihara A; Nishida J; Kanda Y PLoS One; 2013; 8(9):e73754. PubMed ID: 24040054 [TBL] [Abstract][Full Text] [Related]
16. Persistent Primary Cytomegalovirus Infection After Deceased Donor Kidney Transplant: Ganciclovir Susceptibility of Human Cytomegalovirus With UL97 D605E Mutation: A Case Report. Nawashiro Y; Shiraki K; Yamamoto S; Takizawa K; Sasada Y; Suehiro M; Miura K; Hattori M; Daikoku T; Hisano M Transplant Proc; 2018 Dec; 50(10):3932-3936. PubMed ID: 30577289 [TBL] [Abstract][Full Text] [Related]
17. Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies. Majeed A; Latif A; Kapoor V; Sohail A; Florita C; Georgescu A; Zangeneh T Transplant Proc; 2018 Dec; 50(10):3756-3762. PubMed ID: 30586840 [TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Isada CM; Yen-Lieberman B; Lurain NS; Schilz R; Kohn D; Longworth DL; Taege AJ; Mossad SB; Maurer J; Flechner SM; Mawhorter SD; Braun W; Gordon SM; Schmitt SK; Goldman M; Long J; Haug M; Avery RK Transpl Infect Dis; 2002 Dec; 4(4):189-94. PubMed ID: 12535261 [TBL] [Abstract][Full Text] [Related]
19. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Mylonakis E; Kallas WM; Fishman JA Clin Infect Dis; 2002 May; 34(10):1337-41. PubMed ID: 11981729 [TBL] [Abstract][Full Text] [Related]
20. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients. Rho E; Näf B; Müller TF; Wüthrich RP; Schachter T; von Moos S Clin Transplant; 2021 Nov; 35(11):e14401. PubMed ID: 34181768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]